Compare · ACON vs CI
ACON vs CI
Side-by-side comparison of Aclarion Inc. (ACON) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACON and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.58B, about 8711.6x ACON ($8.8M).
- Over the past year, ACON is down 53.0% and CI is down 7.0% - CI leads by 46.0 points.
- ACON has been more active in the news (7 items in the past 4 weeks vs 4 for CI).
- CI has more recent analyst coverage (25 ratings vs 0 for ACON).
- Company
- Aclarion Inc.
- The Cigna Group
- Price
- $3.35-4.01%
- $289.50+0.00%
- Market cap
- $8.8M
- $76.58B
- 1M return
- +2.45%
- +1.94%
- 1Y return
- -53.02%
- -7.00%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 7
- 4
- Recent ratings
- 0
- 25
Aclarion Inc.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest ACON
- Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
- Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
- Aclarion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
- Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
- Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
- Echo Lake Capital Offers To Acquire Aclarion Inc.
- SEC Form 10-Q filed by Aclarion Inc.
- Director Breidbart Scott bought $18,012 worth of shares (5,664 units at $3.18) (SEC Form 4)
- Director Neal David K bought $7,750 worth of shares (2,500 units at $3.10), increasing direct ownership by 125,000% to 2,502 units (SEC Form 4)
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group